Shots:
- RemeGen has granted AbbVie exclusive rights to develop, manufacture, & commercialize RC148 outside of the Greater China
- In return, RemeGen will receive $650M upfront, ~$4.95B in development, regulatory, & commercial milestones, with tiered, double-digit royalties on sales in AbbVie’s licensed areas
- RC148 is a PD-1/VEGF-targeted bispecific antibody that is being developed as a monotx. & in combination regimens across multiple advanced solid tumors
Ref: AbbVie | Image: AbbVie | Press Release
Related News: AbbVie Reports P-III (ECLIPSE) Trial Data on Aquipta (Atogepant) for the Acute Treatment of Migraine
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
